22057 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Hudis
    Hudis
  4. Kris
    Kris
  5. Saltz
    Saltz
  6. Offit
    Offit
  7. O'Reilly
    O'Reilly
  8. Solit
    Solit
  9. Robson
    Robson
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)
  7. Breast Medicine Service (4103)
  8. Surgery (4019)
  9. Department of Pathology and Laboratory Medicine (3422)
  10. Thoracic Oncology (3351)
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors
    Meeting Abstract

    Gao, X.; Patnaik, A.; Lakhani, N. J.; Call, J. A.; Galsky, M. D.; Garmezy, B.; Wei, A. Z.; Carter, L.; Powles, T.; Siefker-Radtke, A. O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Kiess, A. P.; Nordquist, L.; Gupta, S.; George, D. J.; Messmann, R. A.; Kantoff, P. W.; Nauseef, J. T.; Bander, N. H.; Antonarakis, E. S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    Chen, Y. W.; Liu, L.; Cheng, Y.; Araneta, A.; Castano, N.; Gomez, J.; Ajmera, A.; Ye, H.; Runcie, K.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)
    Meeting Abstract

    Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy
    Meeting Abstract

    Tran, B.; Courtney, K. D.; Sokolova, A.; Horvath, L.; Danila, D. C.; Hawley, J. E.; Pook, D. W.; Brown, L. C.; Whang, Y. E.; Buetikofer, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Suárez, C.; Albiges, L.; Beckermann, K.; Hammers, H. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save